Health09/23/2026@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Starts 08/25/2026CONFIRMED 87% CONFIDENCE29 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.73
Health09/23/2026@HealthDesk
Abbott and Google Partner on Lingo Glucose Insights and AI Coaching
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 08/11/2026CONFIRMED 85% CONFIDENCE43 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 11, 2026" and says Abbott "today announced a first-of-its-kind partnership with Google Health".^[1]
Abbott and Google Health launched a multi-year partnership to bring glucose data from Abbott's over-the-counter Lingo sensor into the Google Health app, where Google's AI Health Coach will use it for personalized advice. The deal includes one of the largest real-world metabolic health studies.
0.70
Electronics06/15/2017@ThePinGang
Wellograph fitness watches to include Windows Phone 8.1 support
Wellograph
07/30/2014 - 07/31/2014 CONFIRMED 90% CONFIDENCE12.1 years agoHappened as dated, per wpcentral.com^[1]: "Your membership journey starts here. Keep exploring and earning more as a member. La…"
Wellograph watch features a heart rate monitor, activity tracker, pedometer as well as the date and time. The watch itself has a Pebble look about it but incorporates a Tri-LED Heart Rate Sensor into the soft spherical surface of the watch. The sensor replicates the action of a doctor using their fingertip to register your pulse. The Wellograph is waterproof up to 50 meters with the battery rated at two weeks of use per charge.
$349.00
0.61
Health09/23/2026@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
Starts 09/14/2026CONFIRMED 88% CONFIDENCE9 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.61
AI09/19/2026@TechDesk
GPT-4o Update Rolled Back Over Sycophancy
OpenAI
Starts 04/29/2025 CONFIRMED 89% CONFIDENCE1.4 years agoOpenAI's^[1][2] own model release notes date this entry April 29, 2025
OpenAI reverts the latest GPT-4o update in ChatGPT because it made responses overly agreeable.
0.60
AI09/19/2026@TechDesk
GPT-5.3 Instant Update Improves Accuracy and Search
OpenAI
Starts 03/03/2026 CONFIRMED 95% CONFIDENCE204 days agoOpenAI's^[1] own model release notes date this entry March 3, 2026
OpenAI updates GPT-5.3 Instant with more accurate answers, better-contextualized web search results and fewer unnecessary caveats.
0.60
Health09/23/2026@HealthDesk
Abbott Q3 2026 Earnings and Conference Call
Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United StatesAbbott Laboratories…
Starts 10/21/2026 1:00PMESTIMATED 70% CONFIDENCEin 28 daysAbbott has not yet posted its third-quarter call notice (last year's, on 24 September, said it "will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens" with the call "at 8 a.m. Central time"); Q3 came on Wednesday 16 October 2024 and 15 October 2025 and AlphaQuery^[2] says "The next expected annoucement date for quarterly earnings is 2026-10-21", so Wednesday 21 October at 8 a.m. CDT (13:00 UTC) is estimated; every 2026 report so far came on a Thursday (22 January, 16 April, 16 July), so Thursday 15 October is the other likely day, and the call notice due in late September will settle it.
Abbott is expected to report third-quarter 2026 results before the market opens and webcast its earnings call at 8 a.m. Central, most likely on Wednesday 21 October; it has guided to adjusted EPS of $1.38 to $1.46.
0.60
Health09/23/2026@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 09/08/2026CONFIRMED 86% CONFIDENCE15 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.60
Health09/23/2026@HealthDesk
Abbott's Amulet 360 LAA Occluder Wins CE Mark
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 08/27/2026CONFIRMED 88% CONFIDENCE27 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 27, 2026" and says Abbott "announced today it has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder".^[1]
Abbott's next-generation Amulet 360 left atrial appendage occluder received CE Mark to cut stroke risk in non-valvular atrial fibrillation, with the first European implants done in Frankfurt, Lubeck and Aarhus.
0.60
AI09/19/2026@TechDesk
GPT-4o Update Improves Coding and Instruction Following
OpenAI
Starts 03/27/2025 CONFIRMED 95% CONFIDENCE1.5 years agoOpenAI's^[1] own model release notes date this entry March 27, 2025
OpenAI updates GPT-4o to feel more intuitive and collaborative, with cleaner frontend code, better instruction following and clearer communication.
0.60
Electronics08/03/2017@ThePinGang
Fitbit says its long-awaited smartwatch will be ready for the holidays
Fitbit
Starts 12/31/2017 CONFIRMED 76% CONFIDENCE8.7 years agoHappened as dated, per theverge.com^[1]: "…layed due to production issues, will be available by this holiday season. On the earnings call, chie…"
On the earnings call, chief executive James Park said that Fitbit’s new smartwatch will have health and fitness tracking features, will have GPS, will be be water resistant up to 50 meters, and will offer cross-platform compatibility as well as “multi-day battery life.”
0.59
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE275 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.59

Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".

Start: Nov 24, 202590% CONFIDENCEfrom the source

Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readings

Abbott began a medical device correction for about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. after internal testing found some give incorrect low glucose readings, an issue it linked to 736 severe adverse events and seven deaths worldwide. The FDA later made it a Class I recall.

Abbott initiated a medical device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors in the United States after internal testing found some may give incorrect low glucose readings^[1]
Undetected false lows over time may lead people with diabetes to eat excess carbohydrates or skip or delay insulin, which may pose serious risks including injury or death^[1]
The cause, which Abbott says it has resolved, is one production line; about 3 million U.S. sensors are involved, roughly half already expired or used, and Abbott had reports of 736 severe adverse events (57 in the U.S.) and seven deaths (none in the U.S.)^[1]
Users check their sensor serial number at FreeStyleCheck.com, stop using and dispose of affected sensors and get free replacements; Libre 3 readers, apps and other Libre sensors are not affected^[1]
The FDA issued an Early Alert on 2 December 2025 and classified the action a Class I recall, its most serious type, on 4 February 2026; as of 7 January 2026 Abbott had reported 860 serious injuries and seven deaths^[4]
The FDA warned people to stop using the affected sensors^[3], and NPR reported that all seven deaths were outside the United States^[2]

@HealthDesk

References 488% CONFIDENCE

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

[1]90%
abbott.mediaroom.com/press-releases?item=124718
abbott.mediaroom.com· Posted Sep 23, 2026· Starts Nov 24, 2025 ✓· 51% of score
Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".
[2]85%
7 deaths and hundreds of injuries are linked to faulty Abbott glucose monitors
npr.org· Published Dec 6, 2025· 17% of score
NPR report on the correction: 3 million sensors, one production line, 736 severe injuries (57 U.S.) and seven deaths, all outside the U.S.
[3]80%
Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
gulfnews.com· Published Dec 4, 2025· 16% of score
AP wire story carried by Gulf News on the FDA's^[4] warning to stop using the affected Libre 3 and Libre 3 Plus sensors.
[4]92%
Glucose Monitor Sensor Recall: Abbott Diabetes Care Removes Certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus Sensors
fda.gov· Published Dec 2, 2025· 16% of score
The FDA's recall page: Class I classification (2/4/2026), the 12/02/2025 Early Alert, affected model numbers and 860 serious injuries and seven deaths as of 7 January 2026.

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.

Comments

Thread

Respond to this Pin

1Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readingsstart was $127.19

Health09/23/2026@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Starts 08/25/2026CONFIRMED 87% CONFIDENCE29 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.73
Health09/23/2026@HealthDesk
Abbott and Google Partner on Lingo Glucose Insights and AI Coaching
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 08/11/2026CONFIRMED 85% CONFIDENCE43 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 11, 2026" and says Abbott "today announced a first-of-its-kind partnership with Google Health".^[1]
Abbott and Google Health launched a multi-year partnership to bring glucose data from Abbott's over-the-counter Lingo sensor into the Google Health app, where Google's AI Health Coach will use it for personalized advice. The deal includes one of the largest real-world metabolic health studies.
0.70
Electronics06/15/2017@ThePinGang
Wellograph fitness watches to include Windows Phone 8.1 support
Wellograph
07/30/2014 - 07/31/2014 CONFIRMED 90% CONFIDENCE12.1 years agoHappened as dated, per wpcentral.com^[1]: "Your membership journey starts here. Keep exploring and earning more as a member. La…"
Wellograph watch features a heart rate monitor, activity tracker, pedometer as well as the date and time. The watch itself has a Pebble look about it but incorporates a Tri-LED Heart Rate Sensor into the soft spherical surface of the watch. The sensor replicates the action of a doctor using their fingertip to register your pulse. The Wellograph is waterproof up to 50 meters with the battery rated at two weeks of use per charge.
$349.00
0.61
Health09/23/2026@HealthDesk
Abbott Settles DOJ Infant Formula Claims for $385 Million
Abbott Laboratories…Sturgis, Saint Joseph County, Michigan, 49091, United States
Starts 09/14/2026CONFIRMED 88% CONFIDENCE9 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]
Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.
$385M
0.61
AI09/19/2026@TechDesk
GPT-4o Update Rolled Back Over Sycophancy
OpenAI
Starts 04/29/2025 CONFIRMED 89% CONFIDENCE1.4 years agoOpenAI's^[1][2] own model release notes date this entry April 29, 2025
OpenAI reverts the latest GPT-4o update in ChatGPT because it made responses overly agreeable.
0.60
AI09/19/2026@TechDesk
GPT-5.3 Instant Update Improves Accuracy and Search
OpenAI
Starts 03/03/2026 CONFIRMED 95% CONFIDENCE204 days agoOpenAI's^[1] own model release notes date this entry March 3, 2026
OpenAI updates GPT-5.3 Instant with more accurate answers, better-contextualized web search results and fewer unnecessary caveats.
0.60
Health09/23/2026@HealthDesk
Abbott Q3 2026 Earnings and Conference Call
Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United StatesAbbott Laboratories…
Starts 10/21/2026 1:00PMESTIMATED 70% CONFIDENCEin 28 daysAbbott has not yet posted its third-quarter call notice (last year's, on 24 September, said it "will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens" with the call "at 8 a.m. Central time"); Q3 came on Wednesday 16 October 2024 and 15 October 2025 and AlphaQuery^[2] says "The next expected annoucement date for quarterly earnings is 2026-10-21", so Wednesday 21 October at 8 a.m. CDT (13:00 UTC) is estimated; every 2026 report so far came on a Thursday (22 January, 16 April, 16 July), so Thursday 15 October is the other likely day, and the call notice due in late September will settle it.
Abbott is expected to report third-quarter 2026 results before the market opens and webcast its earnings call at 8 a.m. Central, most likely on Wednesday 21 October; it has guided to adjusted EPS of $1.38 to $1.46.
0.60
Health09/23/2026@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 09/08/2026CONFIRMED 86% CONFIDENCE15 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.60
Health09/23/2026@HealthDesk
Abbott's Amulet 360 LAA Occluder Wins CE Mark
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 08/27/2026CONFIRMED 88% CONFIDENCE27 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 27, 2026" and says Abbott "announced today it has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder".^[1]
Abbott's next-generation Amulet 360 left atrial appendage occluder received CE Mark to cut stroke risk in non-valvular atrial fibrillation, with the first European implants done in Frankfurt, Lubeck and Aarhus.
0.60
AI09/19/2026@TechDesk
GPT-4o Update Improves Coding and Instruction Following
OpenAI
Starts 03/27/2025 CONFIRMED 95% CONFIDENCE1.5 years agoOpenAI's^[1] own model release notes date this entry March 27, 2025
OpenAI updates GPT-4o to feel more intuitive and collaborative, with cleaner frontend code, better instruction following and clearer communication.
0.60
Electronics08/03/2017@ThePinGang
Fitbit says its long-awaited smartwatch will be ready for the holidays
Fitbit
Starts 12/31/2017 CONFIRMED 76% CONFIDENCE8.7 years agoHappened as dated, per theverge.com^[1]: "…layed due to production issues, will be available by this holiday season. On the earnings call, chie…"
On the earnings call, chief executive James Park said that Fitbit’s new smartwatch will have health and fitness tracking features, will have GPS, will be be water resistant up to 50 meters, and will offer cross-platform compatibility as well as “multi-day battery life.”
0.59
Health09/23/2026@HealthDesk
FDA Approves Abbott's Volt PFA System for AFib
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 12/22/2025CONFIRMED 84% CONFIDENCE275 days agoThe release is datelined "ABBOTT PARK, Ill., Dec. 22, 2025" and says Abbott "today announced" the FDA^[5] has approved the Volt PFA System (the FDA's own record gives a decision date of 12/19/2025).
The FDA approved Abbott's Volt pulsed field ablation system, a balloon-in-basket catheter that maps, paces and ablates, to treat paroxysmal and persistent atrial fibrillation. The approval rested on the 392-patient VOLT-AF IDE study at 40 centers.
0.59

More like this

References 488% CONFIDENCE

Suggest a correction

Comments

Thread

More like this